@article {Friedlander771, author = {Michael Friedlander and Edward Trimble and Anna Tinker and David Alberts and Elisabeth Avall-Lundqvist and Mark Brady and Philipp Harter and Sandro Pignata and Eric Pujade- Lauraine and Jalid Sehouli and Ignace Vergote and Philip Beale and Rudd Bekkers and Paula Calvert and Lawrence Copeland and Ros Glasspool and Antonio Gonzalez-Martin and Dionysis Katsaros and Jae Won Kim and Brigitte Miller and Diane Provencher and Lawrence Rubinstein and Mostafa Atri and Alain Zeimet and Monica Bacon and Henry Kitchener and Gavin C.E. Stuart}, title = {Clinical Trials in Recurrent Ovarian Cancer}, volume = {21}, number = {4}, pages = {771--775}, year = {2011}, doi = {10.1097/IGC.0b013e31821bb8aa}, publisher = {BMJ Specialist Journals}, abstract = {The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/21/4/771}, eprint = {https://ijgc.bmj.com/content/21/4/771.full.pdf}, journal = {International Journal of Gynecologic Cancer} }